Medical/Pharmaceuticals

The Benefits of Prostate Cancer Screening Outweigh the Harms, According to New Patient Guidelines From NCCN

Free, comprehensive guidebook shows how prostate cancer screening has largely deemphasized invasive testing in order to avoid unnecessary procedures and treatment while at the same time saving lives. PLYMOUTH MEETING, Pa., April 28, 2026 /PRNewswire/ -- The National Comprehensive Cancer Network®...

2026-04-28 22:04 3816

ACROBiosystems Showcases AI-Driven Innovation at AACR 2026, Empowering Next-Generation Biologics Discovery

SAN DIEGO and NEWARK, N.J., April 28, 2026 /PRNewswire/ -- From April 17 to 22, 2026, ACROBiosystems—a company dedicated to being a cornerstone of the global biopharmaceutical and healthcare industries—presented its comprehensive, AI‑driven protein solutions at the American Association for Cancer...

2026-04-28 22:00 3144

C-Ray Therapeutics Receives FDA Acceptance of Type II Drug Master File for Copper-64 (Cu-64)

DMF No. 43568 is now active and available for reference in global IND and NDA submissions CHENGDU, China, April 28, 2026 /PRNewswire/ -- C-Ray Therapeutics (Chengdu) Co., Ltd., today announced that its Type II Drug Master File (DMF) for COPPER [64Cu] CHLORIDE FOR RADIOLABELLING has been listed a...

2026-04-28 21:11 2195

Nuevocor Appoints Dr. Monica Shah as Chief Medical Officer

SINGAPORE, PARIS and PHILADELPHIA, April 28, 2026 /PRNewswire/ -- Nuevocor, a clinical-stage biotechnology company developing novel therapies for patients suffering from life-threatening cardiomyopathies, today announced the appointment of Monica Shah, MD, FACC, as Chief Medical Officer. Dr. Shah...

2026-04-28 21:05 2616

World's First Recombinant Botulinum Toxin Type A New Drug Received Marketing Approval in China: a Technological Revolution pioneered by Claruvis Pharmaceutical

CHONGQING, China, April 28, 2026 /PRNewswire/ -- Chongqing Claruvis Pharmaceutical Co., Ltd. recently announced that the China's National Medical Products Administration (NMPA) has approved its Retoxin® (recombinant botulinum toxin type A, project code YY001) for the temporary improvement of mod...

2026-04-28 20:38 2751

Echosens Appoints Romain Baujard as Group Chief Executive Officer

Company to accelerate its mission to make liver health a vital sign in cardiometabolic care; appointment follows retirement of current Group CEO Dominique Legros PARIS, April 28, 2026 /PRNewswire/ -- Echosens , a global diagnostic company specializing in non-invasive m...

2026-04-28 20:00 1865

HoneyNaps Expands into Boston's Kendall Square, Accelerating Global Partnerships in AI Sleep Healthcare

* New office in Boston-Cambridge innovation hub to expand partnerships with healthcare and life sciences leaders * Supported through a Korea Health Industry Development Institute global expansion program * Strategic move expected to accelerate commercialization, clinical collaborations, and...

2026-04-28 19:00 2438

Kuching to Host Malaysia's First CIFA Regional Symposium

KUCHING, Malaysia, April 28, 2026 /PRNewswire/ -- Malaysia has been selected to host the Consortium of Institutes on Family in the Asian Region (CIFA) Regional Symposium 2026, co-organised by the National Coalition for Mental Wellbeing (NCMW) Malaysia and CIFA Hong Kong, with Kuching making histor...

2026-04-28 16:52 2770

Ivonescimab Receives Major Recommendations Across Multiple Therapies in the 2026 CSCO NSCLC Guideline

HONG KONG, April 28, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") today announced that ivonescimab, the company's first-in-class PD-1/VEGF bispecific antibody, has secured multiple authoritative updates and upgrades across first-line and later-line settings in the officia...

2026-04-28 16:07 2783

3Shape Receives FDA 510(k) Clearance for 3Shape Dx Software

COPENHAGEN, Denmark, April 28, 2026 /PRNewswire/ -- 3Shape today announced that the U.S. Food and Drug Administration (FDA) has granted FDA clearance for its Dx Software following a review completed on April 10. 2026. The 510(k) Premarket Notification allows Dx (R1) software to be commercially a...

2026-04-28 15:43 2715

HistoIndex Extends Access To Its MASH Diagnostic Offering Through New Partnerships In Texas And California

SINGAPORE, April 28, 2026 /PRNewswire/ -- HistoIndex, a pioneer in AI-driven digital pathology solutions for chronic liver disease, has announced the continued expansion of its commercial partnership network in the United States with the addition of two new hepatology and gastroenterology centers...

2026-04-28 15:30 3542

Australian company unlocks a new era for women's health globally with an innovative delivery system for Female testosterone in women with low libido

* Massive unmet need for Hypoactive Sexual Desire Disorder treatments addressed by new Female Testosterone product * Phase I and II clinical trials completed. Phase III to be done in co-development with global partners. * Unique, Australian developed unique Patchless Patch™ delivery technolo...

2026-04-28 14:25 2421

BLINDED ASSESSMENT OF ACTION3 STATISTICAL ASSUMPTIONS COMPLETE

Key Highlights: * An external statistical blinded review of ACTION3 data has achieved its objective by confirming that the study remains appropriately statistically powered (>90%) to demonstrate a treatment effect for the primary study endpoint of proteinuria; meaning that if DMX-200 continues...

2026-04-28 10:17 2352

Cordis Launches SELUTION SLR™ PTA Drug-Eluting Balloon (DEB) in Japan

TOKYO, April 28, 2026 /PRNewswire/ -- Cordis, a global leader in interventional cardiovascular technologies, today announces the launch and availability of the SELUTION SLR™ PTA Drug-Eluting Balloon (DEB)1 for use in Japan. SELUTION SLR™ DEB is designed to deliver sirolimus in a controlled, susta...

2026-04-28 09:00 3098

Educational Webinar: Unlocking the Potential of PSMA Therapy, A Next‑Generation Portfolio Approach

MELBOURNE, Australia and INDIANAPOLIS, April 28, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") announces an educational webinar exploring the evolution of PSMA[1]-targeted radionuclide therapy and Telix's differentiated, multi-product approach to treating pros...

2026-04-28 07:44 2738

Cellenkos, Inc. Announces FDA Clearance to Initiate Phase 2 Clinical Trial of CK0801 (Allogeneic Cord Blood-Derived Tregs) for Aplastic Anemia

Phase 2 multicenter, open-label study (NCT07499102) will evaluate the safety and clinical efficacy of CK0801 Tregs in transfusion-dependent aplastic anemia. HOUSTON, April 27, 2026 /PRNewswire/ -- Cellenkos®, Inc., a clinical-stage biotechnology company, developing allogeneic, tissue-targeted reg...

2026-04-27 23:19 4214

The EXCEL - First-of-its-kind study highlights critical role of essential phospholipids in improving Fatty Liver Disease

PARIS, April 27, 2026 /PRNewswire/ -- A new study has established that treatment with essential phospholipids (Essentiale) resulted in a 2.5 times greater reduction in liver fat, significant improvement in fatigue and improvement of glycaemic control in individuals with Metabolic dysfunction–Ass...

2026-04-27 23:18 4011

CONCEPT MEDICAL ANNOUNCES PRELIMINARY 3-YEAR SIRONA DATA AT CHARING CROSS SYMPOSIUM 2026

LONDON, April 27, 2026 /PRNewswire/ -- Concept Medical Inc. , today announced the presentation of preliminary 3-year follow-up data from theSIRONA randomised trial at the Charing Cross (CX) Symposium 2026, reinforcing its leadership in drug-delivery technologies ...

2026-04-27 23:17 3125

Sarawak Secures Landmark Win to Host APAC's Leading Lung Disease Conference in 2028

KUCHING, Malaysia, April 27, 2026 /PRNewswire/ -- Sarawak has won hosting rights for the 11th Asia Pacific Regional Conference 2028 (APRC 2028) of the International Union Against Tuberculosis and Lung Disease, marking a significant milestone in the destination's continued rise as the legacy capit...

2026-04-27 22:11 2808

AHG Announces Initiation of World-Class, Proprietary Brain-Computer Interface R&D Program - Targeting the Next Frontier of Human Neurotechnology

QINGDAO, China, April 27, 2026 /PRNewswire/ -- Akso Health Group (NASDAQ: AHG) ("Akso Health" or the "Company") today announced the commencement of its next-generation, proprietary Brain-Computer Interface (BCI) technology research and development program. The Company is establishing the foundati...

2026-04-27 21:00 3028
123456 ... 649

Week's Top Stories